JASMINE KAUR: Open Payments
NPI 1992113492 · SAN JOSE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,355 in 43 payments from 7 companies in 2025. Trend: 2023 $354 · 2024 $985 · 2025 $1,355
Food & beverage: $1,355
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $459 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $278 |
| Axsome Therapeutics, Inc. | 5 | $249 |
| Janssen Pharmaceuticals, Inc | 1 | $143 |
| Otsuka America Pharmaceutical, Inc. | 1 | $131 |
| Vanda Pharmaceuticals Inc. | 2 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
Products named: VRAYLAR, CAPLYTA, Auvelity, INVEGA SUSTENNA, ABILIFY MAINTENA, FANAPT, TRINTELLIX.
Industry payments across CA — which companies pay providers there.
